Cargando…
Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'nordic' phase III study.
The study was planned to compare, in a prospective double-blind randomized trial, the efficacy and safety of toremifene (TOR) and tamoxifen (TAM) in post-menopausal patients with advanced breast cancer who have not had prior systemic therapy for advanced disease. Four hundred and fifteen post-menopa...
Autores principales: | Pyrhönen, S., Valavaara, R., Modig, H., Pawlicki, M., Pienkowski, T., Gundersen, S., Bauer, J., Westman, G., Lundgren, S., Blanco, G., Mella, O., Nilsson, I., Hietanen, T., Hindy, I., Vuorinen, J., Hajba, A. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1997
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2223944/ https://www.ncbi.nlm.nih.gov/pubmed/9231932 |
Ejemplares similares
-
Prospective study on gynaecological effects of two antioestrogens tamoxifen and toremifene in postmenopausal women
por: Marttunen, M B, et al.
Publicado: (2001) -
K-ras mutation in the endometrium of tamoxifen-treated breast cancer patients, with a comparison of tamoxifen and toremifene
por: Hachisuga, T, et al.
Publicado: (2005) -
Effects of Tamoxifen vs. Toremifene on fatty liver development and lipid profiles in breast Cancer
por: Song, Dandan, et al.
Publicado: (2021) -
Circumvention of Daunorubicin Resistance by a New Tamoxifen Derivative, Toremifene, in Multidrug‐resistant Cell Line
por: Urasaki, Yoshimasa, et al.
Publicado: (1994) -
Breast cancer risk estimation in families with history of breast cancer.
por: Muhonen, T., et al.
Publicado: (1997)